Figure 1.

Tim-1-Fc attenuates chronic cardiac rejection in MHC II mismatched cardiac grafts. A: Survival rate of Bm12-derived cardiac grafts in B6 recipients treated with either Tim-1-Fc or control IgG. Loss of graft function was defined as cessation of a palpable impulse. B: Hematoxylin and eosin (H&E) staining of cardiac graft sections harvested after day 35 of transplantation. C: Scores for the severity of vasculopathy in cardiac grafts after day 35 of transplantation. D: Intragraft expression of IL-2, IL4, IFN-γ, IL-17 and IL-6. The relative expression levels of cytokines within the grafts were assessed by real-time PCR. E: Administration of recombinant IL-17 abolished the protective effect conferred by Tim-1-Fc. Recombinant IL-17 was administrated along with Tim-1-Fc or control IgG after transplantation every other day until day 15. Histological data and real-time PCR data were obtained from studies of 3 mice.